Vigil Neuroscience, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Vigil Neuroscience, Inc. announced the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period, a significant step towards its acquisition by Sanofi.
DEFM14A: Vigil Neuroscience to be Acquired by Sanofi for $10.00 Per Share, Including Contingent Value Right
Vigil Neuroscience, a clinical-stage biotechnology company, has entered into a definitive merger agreement to be acquired by Sanofi for $8.00 per share in upfront cash plus a contingent value right of $2.00 per share, contingent on the achievement of a key clinical milestone for VG-3927.
Vigil Neuroscience and Sanofi have entered into a merger agreement where Sanofi will acquire Vigil, pending stockholder and regulatory approvals.
Vigil Neuroscience is set to be acquired by Sanofi, aiming to advance TREM2 agonist program for Alzheimer's disease and returning VGL101 to Amgen.
Sanofi is set to acquire Vigil Neuroscience for $8.00 per share in cash upfront, plus a contingent value right (CVR) of up to $2.00 per share, pending regulatory and stockholder approvals, with the transaction expected to close in the third quarter of 2025.
DEFA14A: Sanofi to Acquire Vigil Neuroscience for Up to $600 Million, Bolstering Alzheimer's Disease Pipeline
Sanofi is set to acquire Vigil Neuroscience in a deal valued at up to $600 million, gaining access to Vigil's TREM2 agonist pipeline, including the Phase 2-ready candidate VG-3927 for Alzheimer's disease.
DEFA14A: Vigil Neuroscience Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote
Vigil Neuroscience announces its 2025 Annual Meeting of Stockholders, urging investors to vote on key proposals including the election of directors and ratification of the company's accounting firm.
Vigil Neuroscience announces its 2025 Annual Meeting of Stockholders to be held virtually on May 22, 2025, featuring director elections and ratification of the company's accounting firm.
Vigil Neuroscience's upcoming annual meeting on June 5, 2024, will address the election of directors, ratification of the accounting firm, and an amendment to the company's certificate of incorporation.
Vigil Neuroscience's upcoming annual meeting on June 5, 2024, will address the election of three Class III directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and an amendment to limit officer liability.